Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis

Respiratory Medicine

Volumn 100, Issue 10, 2006, Pages 1706-1715

  Walter Canonica, G ^a   Bousquet, Jean ^b   Van Hammée, Geneviève ^c   Bachert, Claus ^d   Durham, Stephen R ^e   Klimek, Ludger ^f   Mullol, Joaquim ^g   Van Cauwenberge, Paul B ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c UCB PHARMA   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f Center for Rhinology and Allergy   (Germany)

^g HOSPITAL CLÍNIC   (Spain)

Author keywords

Health related quality of life; Levocetirizine; Persistent allergic rhinitis; RQLQ; SF 36

Indexed keywords

LEVOCETIRIZINE; PLACEBO;

ALLERGIC RHINITIS; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; HEALTH STATUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT OUTCOME;

CETIRIZINE; DOUBLE-BLIND METHOD; HEALTH STATUS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; PIPERAZINES; QUALITY OF LIFE; QUESTIONNAIRES; RHINITIS, ALLERGIC, PERENNIAL; TREATMENT OUTCOME;

EID: 33747818877     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.03.039     Document Type: Article

References (38)

1. Jones N.S. The prevalence of allergic rhinosinusitis: a review. J Laryngol Otol 112 (1998) 1019-1030
2. Bellanti J.A., and Wallerstedt D.B. Allergic rhinitis update: epidemiology and natural history. Allergy Asthma Proc 21 (2000) 367-370
3. Ciprandi G., Vizzaccaro A., Cirillo I., et al. Increase of asthma and allergic rhinitis prevalence in young Italian men. Int Arch Allergy Immunol 111 (1996) 278-283
4. Spector S.L. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 99 (1997) S773-S780
5. Bousquet J., Van Cauwenberge P., Khaltaev N., and Bachert C. Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organisation. Executive summary of the workshop report. Allergy 57 (2002) 841-855
6. Bousquet J., Van Cauwenberge P., Bachert C., et al. Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 58 (2003) 192-197
7. Van Cauwenberge P. Consensus statement on the treatment of allergic rhinitis. Allergy 55 (2000) 116-134
8. Juniper E.F. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 99 (1997) S742-S749
9. Majani G., Baiardini I., Giardini A., et al. Allergic rhinitis and quality of life: Where are we?. Clin Exp Allergy Rev 3 (2003) 90-94
10. Bousquet J., Duchateau J., Pignat J.C., et al. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 98 (1996) 309-316
11. Juniper E.F. Rhinitis management: the patient's perspective. Clin Exp Allergy 28 (1998) S34-S38
12. Baiardini I., Pasquali M., Giardini A., et al. Quality of life in respiratory allergy. Allergy Asthma Proc 22 (2001) 177-181
13. Meltzer E.O. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 108 (2001) S45-S53
14. McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy 73 (1994) 35-39
15. Bachert C. Importance of quality of life in patients with seasonal allergic rhinitis. Rev fr Allergol 40 (2000) 74-77
16. Ciprandi G., Cirillo I., Viccazzaro A., et al. Seasonal and perennial allergic rhinitis: is this classification adherent to real life?. Allergy 60 (2005) 882-887
17. Bousquet J., Van Cauwenberge P., and Khaltaev N. ARIA Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108 (2001) S147-S334
18. Demoly P., Allaert F.A., Lecasble M., and Bousquet J. PRAGMA. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy 58 (2003) 672-675
19. Bauchau V., and Durham S. Epidemiological characterization of the intermittent and persistent sub-types of allergic rhinitis. Allergy 60 (2005) 350-353
20. Bachert C., Bousquet J., Canonica G.W., et al. Levocetirizine improves quality-of-life and reduces costs in long term treatment of persistent allergic rhinitis. J Allergy Clin Immunol 114 (2004) 838-844
21. Fayers P.M., and Machin D. Quality of life: assessment, analysis and interpretation (2000), John Wiley, Chichester
22. Bliven B.D., Kaufman S.E., and Spertus J.A. Electronic collection of health-related quality of life data: validity, time benefits, and patient preference. Qual Life Res 10 (2001) 15-22
23. Ryan J.M., Corry J.R., Attewell R., and Smithson M.J. A comparison of an electronic version of the SF-36 General Health Questionnaire to the standard paper version. Qual Life Res 11 (2002) 19-26
24. Bushnell D.M., Martin M.L., and Parasuraman B. Electronic versus paper questionnaires: a further comparison in persons with asthma. J Asthma 40 (2003) 751-762
25. Juniper E.F., and Guyatt G.H. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21 (1991) 77-83
26. Ware J.E., Snow K.K., Kosinski M., and Gandek M. SF-36 health survey. Manual and interpretation guide (1993), The Health Institute, Boston New England Medical Center
27. Ware J.E., Kosinski M., and Keller S.D. SF-36 physical and mental health summary scales: a user's manual (1994), Health Assessment Lab, New England Medical Center, Boston
28. Baiardini I., Pasquali M., Giardini A., et al. Rhinasthma: a new specific QoL questionnaire for patients with rhinitis and asthma. Allergy 58 (2003) 289-294
29. Demoly P., Allaert F.A., and Lecasble M. PRAGMA. ERASM, a pharmacoepidemiology survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy 57 (2002) 546-554
30. Downie S.R., Andersson M., Rimmer J., et al. Symptoms of persistent allergic rhinitis during a full calendar year in house dust mite-sensitive subjects. Allergy 59 (2004) 406-414
31. Bousquet J, Bachert C, Canonica WG, et al. Levocetirizine enhances the health status of patients with persistent allergic rhinitis. XXIII EAACI Congress Abstract Book, 2004. p. 83.
32. Leynaert B., Neukirch C., Liard R., Bousquet J., and Neukirch F. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med 162 (2000) 1391-1396
33. Bousquet J., Bullinger M., Fayol C., Marquis P., Valentin B., and Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 94 (1994) 182-188
34. Cauwenberge P., Juniper E.F., and the Star study investigating group. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 30 (2000) 891-899
35. Noonan M.J., Raphael G.D., Nayak A., et al. The health-related quality of life effects of once-daily cetirizine HCl in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin Exp Allergy 33 (2003) 351-358
36. Juniper E.F., Guyatt H.G., Griffith L.E., et al. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 98 4 (1996) 843-845
37. Simons E.F.S., and Simons R. H1-antihistamines: more relevant than ever in the treatment of allergic disorders. J Allergy Clin Immunol 112 (2003) S42-S52
38. Ciprandi G., Passalacqua G., Mincarini M., et al. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol 79 (1997) 507-511